Sphera Funds Management LTD. grew its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 53.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 116,517 shares of the biotechnology company’s stock after purchasing an additional 40,401 shares during the period. Sarepta Therapeutics comprises 1.4% of Sphera Funds Management LTD.’s holdings, making the stock its 16th largest holding. Sphera Funds Management LTD. owned 0.17% of Sarepta Therapeutics worth $12,716,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Delek Group Ltd. acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $3,457,000. Polar Capital LLP grew its position in Sarepta Therapeutics by 301.0% during the 4th quarter. Polar Capital LLP now owns 200,482 shares of the biotechnology company’s stock valued at $21,879,000 after purchasing an additional 150,482 shares during the last quarter. Casdin Capital LLC grew its position in Sarepta Therapeutics by 275.0% during the 4th quarter. Casdin Capital LLC now owns 150,000 shares of the biotechnology company’s stock valued at $16,370,000 after purchasing an additional 110,000 shares during the last quarter. American International Group Inc. grew its position in Sarepta Therapeutics by 7.3% during the 4th quarter. American International Group Inc. now owns 1,605 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 109 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Sarepta Therapeutics by 11.4% during the 4th quarter. Geode Capital Management LLC now owns 658,753 shares of the biotechnology company’s stock valued at $71,889,000 after purchasing an additional 67,601 shares during the last quarter.
NASDAQ:SRPT traded down $1.83 during mid-day trading on Thursday, reaching $130.77. 200,678 shares of the stock were exchanged, compared to its average volume of 1,591,789. The company has a market capitalization of $9.55 billion, a PE ratio of -23.95 and a beta of 2.08. The company has a quick ratio of 7.49, a current ratio of 8.21 and a debt-to-equity ratio of 0.41. Sarepta Therapeutics Inc has a 1 year low of $70.50 and a 1 year high of $176.50.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.08) by $0.23. The company had revenue of $84.40 million during the quarter, compared to analysts’ expectations of $84.83 million. Sarepta Therapeutics had a negative return on equity of 36.73% and a negative net margin of 120.22%. The business’s revenue for the quarter was up 47.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.37) earnings per share. As a group, sell-side analysts anticipate that Sarepta Therapeutics Inc will post -5.17 EPS for the current fiscal year.
A number of equities research analysts have commented on SRPT shares. Cantor Fitzgerald raised their target price on shares of Sarepta Therapeutics from $217.00 to $231.00 and gave the stock an “overweight” rating in a research note on Thursday, February 28th. Morgan Stanley raised their target price on shares of Sarepta Therapeutics from $161.00 to $169.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Citigroup raised their target price on shares of Sarepta Therapeutics from $188.00 to $201.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Nomura raised their target price on shares of Sarepta Therapeutics from $205.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, February 28th. Finally, BTIG Research set a $190.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, February 5th. Four analysts have rated the stock with a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $185.55.
In other news, SVP David T. Howton sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $140.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the senior vice president now directly owns 31,196 shares of the company’s stock, valued at approximately $4,367,440. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Sandesh Mahatme sold 65,000 shares of the company’s stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $130.23, for a total value of $8,464,950.00. Following the transaction, the chief financial officer now directly owns 14,118 shares of the company’s stock, valued at $1,838,587.14. The disclosure for this sale can be found here. In the last 90 days, insiders sold 160,000 shares of company stock worth $22,089,950. Insiders own 7.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Sphera Funds Management LTD. Increases Position in Sarepta Therapeutics Inc (SRPT)” was originally reported by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://macondaily.com/2019/03/14/sphera-funds-management-ltd-increases-position-in-sarepta-therapeutics-inc-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Featured Story: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.